medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2015, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (3)

Adverse effects of transfusion chain at the Institute of Hematology and Immunology

Martínez MA, Rivero JRA, Fernández DN

Language: Spanish
References: 36
Page: 288-300
PDF size: 167.54 Kb.


ABSTRACT

Introduction: hemovigilance requires an organized control over adverse effects and reactions manifested in blood donors and recipients as well as epidemiologically follow up during the whole transfusional chain.
Aim: to determine the accuracy of the report of adverse reactions in donation and transfusion processes in order to establish an hemovigilance system.
Methods: a descriptive study was performed with data obtained from donation and transfusion registries from 2009 to 2011 of the Department of Transfusion Medicine of the Institute of Hematology and Immunology. Results of the initial research of blood transmitted infections were analized according to the tests recognized in the Cuban blood bank network, as well as the number of patients receiving transfusion of different hemoderivates and reports of classified adverse reactions, according to transfusion medicine procedures. Absolute values and relative frequencies of each variable were calculated and frequencies compared.
Results: 4 456 blood donors were processed, only 83 (1,83 %) were female and 216 were rejected due to positive serological studies; 13 884 patients were transfused using a total of 25 592 units of the different blood components. Only 50 adverse reactions to transfusion were reported (40 immediate and 10 delayed), all of an immune origin. Possible omissions in notification of non-immune adverse reactions to transfusion or during the donation process were considered.
Conclusions: donation and transfusion adverse reactions reporting system must be reinforced emphasizing in delayed non-immune reactions such as those of an infectious origin.


REFERENCES

  1. Organización Mundial de la Salud. Base Mundial de Datos sobre Seguridad de la Sangre, 2011. [Base de datos en Internet]. Disponible en: http://www.who.int/bloodsafety/global_database/GDBS_Summary_Report_2011.pd f?ua=1. (Accedido: 21 de enero de 2014.)

  2. OPS. OMS. Resolución de Mejoramiento de la disponibilidad y calidad de las transfusiones en las Américas de 2008. Resolución CD48.R7. Washington, EUA: 48vo. Consejo Directivo, 60ma. Sesión del Comité Regional de la OPS; 2008. (Sep. 29-Oct. 3, 2008).

  3. Rivero-Jiménez RA. Transmisión de enfermedades bacterianas y parasitarias por transfusiones de sangre y sus componentes. Rev Cubana Hematol Inmunol Hemoter [serie en Internet]. 2008 Ene-Abr [citado 21 Dic 2008]24(1):[aprox. 8 p.] Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892008000100001&lng=es

  4. Rivero-Jiménez RA, Merlín-Linares JC, Blanco de Armas M, Navea-Leyva LM, Lam-Díaz RM, Castillo-González D, et al. Eficacia diagnóstica de sistemas de inmunoensayos para el virus de la hepatitis C en muestras de pacientes multitransfundidos. Rev Cubana Hematol Inmunol Hemoter [revista en la Internet]. 2009 Dic [citado 2013 Jun 20];25(3):Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892009000300006&lng=es

  5. Rivero-Jiménez RA. Transmisión de infecciones virales por la transfusión de sangre. Rev Cubana Hematol Inmunol Hemoter [revista en la Internet]. 2006 Ago [citado 2013 Jun 20];22(2): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892006000200002&lng=es

  6. Rerambiah LK, Rerambiah LE, Bengone C, Djuba Siawaya JF. The risk of transfusión-transmitted viral infections at the Ghana. National Blood Transfusion Centre. Blood Transfus. 2013;Dec:1-4. doi:10:2450/2013.0144-13

  7. Alhetheel A, El-Hazmi MM. Hepatitis G, virus in Saudi blood donors and chronic hepatitis B and C patients. J Infect Dev Ctries. 2014 Jan 15;8(1):110-5. doi:10.3855/jidc.3796.

  8. Petersen LR, Stramer SL, Powers AM. Chikungunya virus: possible impact on transfusion medicine. Transfus Med Rev. 2010;24(1):15-21.

  9. Leal-Noval SR, Fernández E, Arellano V, Martínez C. Efectos adversos de la transfusion de sangre conservada. ¿Qué hay de verdad y que se puede hacer? Haematologica. 2011;96(extra1):25-7.

  10. Murphy MF, Stanworth SJ, Yazer EM. Transfusion practice and safety: current status and possibilities for improvenment. Vox Sanguinis. 2011;100:46-59.

  11. Silva Ballester, HM. Programa de Hemovigilancia para los servicios de salud en la provincia de matanzas. Tesis Doctoral. Disponible en: http://tesis.repo.sld.cu/436/1/SilvaBallester.pdf (Accedido: 21 de enero de 2014).

  12. Knowles S, Chen H. On behalf of the Serious Hazards of transfusión. The 2010 Annual SHOT report. (SHOT) Steering Group; 2011.

  13. Ballester JM, Alfonso ME, Ballester L, Bencomo AA, Cortina L, Macías C, et al. Procederes de bancos de sangre y servicios de transfusiones. La Habana: Instituto de Hematología e Inmunología, Organización Panamericana de la Salud; 2004.

  14. Ballester Santovenia JM, Alfonso Valdés ME, Bencomo Hernández A, Castillo Gonzáles D, Cortina Rosales L, López de Roux MR, et al. ABC de la Medicina Transfusional. Guías Clínicas. La Habana: MINSAP;2006. p. 26-93.

  15. De Sousa G, Muñiz Díaz E, Seghatchian J. Commentary from the European School of Transfusion Medicine (ESTM) course: Controversies and emerging issues in Transfusion Medicine. Transf Apher Sci. 2009;40(2):139-44.

  16. Steinsvao CT, Espinosa A, Flesland O. Eight year’s wit haemovigilance in Norway. What have we learnt? Tranfus Apher Sci. 2013 Dec;49(3):548-52. Doi: 10.1018j.transci.2013.09.013.

  17. Koch CG1, Figueroa PI, Li L, Sabik JF 3rd, Mihaljevic T, Blackstone EH. Red blood cell storage: how long is too long? Ann Thorac Surg. 2013;96(5):1894-9.

  18. Gobierno de España. Secretaría General de Sanidad. Dirección General de Salud Pública y Sanidad Exterior. Subdirección General de Promoción de la Salud y Epidemiología. Informe de Hemovigilancia 2010. Disponible en: http://www.msssi.gob.es/profesionales/saludPublica/medicinaTransfusional/hemovi gilancia/docs/Informe2010_reducido.pdf (Accedido: 21 de enero de 2014)

  19. Instituto Nacional de Salud. Manual de Hemovigilancia. Bogotá, 2010. Disponible en: http://www.ins.gov.co/lineas-de-accion/Red-Nacional- Laboratorios/Publicacio/Manual%20de%20Hemovigilancia.pdf (Accedido: 21 de enero de 2014).

  20. Faber JC. Haemovigilance: definition and overwied of current Hemovigilance Systems. Transfus Altern Transfus Med. 2003;5(1):237-45.

  21. AABB. Manual Técnico. I5va Ed. American Association of Blood Banks. Asociación Argentina de Hemoterapia e Inmunohematología. Buenos Aires, 2007.

  22. Rodríguez González I, Fernández Molina C, Martínez Salgueiro MB. Falsos biológicos positivos por VDRL en el diagnóstico serológico de la sífilis. Rev Cubana Med Trop [revista en la Internet]. 2006 Abr [citado 2014 Ago 13];58(1): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0375- 07602006000100015&lng=es

  23. Afredi SQ, Zahid MN, Shabbir MZ, Hussain Z, Mukhtar N, Tipu MY et al. Prevalence of HCV genotypes in district Mardam. Virology J.l 2013;10:90-4.

  24. Martins PR, Martins RA, Barbosa Vde F, Pereira Gde A, Moraes-Souza H, Silva SS. The importance of hemovigilance in the transmission of infectious diseases. Rev Bras Hematol Hemoter. 2013;35(3):180-4.

  25. Yazdanbakhsh K, Ware RE, Noizart-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors and transfusion management. Blood. 2012;120(3):528-37.

  26. Carson Jl, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB,Fung MK, et al. Red Blood cell transfusión: A Clinical Practice Guideline. From the AABB. Annals of Internal Medicine. 2012;157:49-58.

  27. Perez-Ulloa LE, Rubio-Rubio R, Suárez-Escandón A, Cádiz-Lahens A, Ballester- Santovenia JM. Breve análisis del comportamiento de la hemoterapia en Cuba en el año 2011. Rev Cubana Hematol Inmunol Hemoter. 2012 Dic;28(4):435-8.

  28. Kumar P, Thapliyal R, Coshic P, Chatterjee K. Retrospective evaluation of adverse transfusion reactions following blood product transfusion from a tertiary care hospital: A preliminary step towards hemovigilance. Asian J Transfus Sci. 2013 Jul;7(2):109-15.

  29. Ministerio de Salud Pública. Proyecciones de la Salud Pública en Cuba para el año 2015. [Monografía en Internet]. La Habana: Ciencias Médicas; 2006. [Citado 10 Oct 2009]. Disponible en: http://salud2015.sld.cu

  30. Covin RB, Rich NL, Aysola A. Upper-extremity deep venous thrombosis complicating whole-blood donation. Transfusion. 2004;44:586-90.

  31. Domen RE, Hoeltge GA. Allergic transfusion reactions. An evaluation of 273 consecutive reactions. Arch Pathol Lab Med. 2003;127:316-20.

  32. France CR, Rader A, Carlson B. Donors who react may not come back: analysis of repeat donation as a function of phlebotomist rating of vasovagal reactions. Transfus Apher Sci. 2005;33:99-106.

  33. Linden JV, Wagner K, Voytovich AE, et al. Transfusion errors in New York State: An analysis of 10 years' experience. Transfusion. 2000;40:1270-13.

  34. Jain A, Kaur R. Hemovigilance and blood safety. Asian J Transfus Sci. 2012 Jul;6(2):137-8.

  35. Hemovigilance: An Effective Tool for Improving Transfusion Safety.Rene R. P. De Vries, Jean-Claude Faber (Editors). Amsterdam: Wiley-Blackwell;2012.

  36. Carneiro-Proietti AB. Hemovigilance: a system to improve the whole transfusion chain. Rev Bras Hematol Hemoter.2013;35(3):158-9.




2020     |     www.medigraphic.com